A Phase 1 interventional study of CDR132L in Heart Failure, sponsored by Cardior Pharmaceuticals GmbH. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-09.
Sponsored by Cardior Pharmaceuticals GmbH (part of Novo Nordisk A/S) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Heart Failure by Novo Nordisk A/S — 5 open to participants now, 6 under way, 2 of them phase 3. Heart Failure · Novo Nordisk A/S.
Among the 14 studies in Heart Failure by Novo Nordisk A/S, this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2019, is one of 4 in phase 1, and was the 1st registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →5 of the 14 studies in Heart Failure by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Germany
Ages 18–55 · Healthy volunteers
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 24 more countries
Ages 18+
Novo Nordisk A/S · Sites in United Kingdom
Ages 40–75
Novo Nordisk A/S · Sites in Australia, Czechia, Germany and 7 more countries
Ages 40–84
Novo Nordisk A/S · Sites in United States, Canada, Germany and 6 more countries
Ages 40–84
By country, each count listing its studies:
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 1 started in 2019.
This study's enrollment of 28 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 200 across the 11 interventional studies, 18,198 across the 3 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Cardior Pharmaceuticals GmbH, one of the names counted as Novo Nordisk A/S. Under that name alone:
Cardior Pharmaceuticals GmbH is the lead sponsor of 3 studies on the registry; none are open to participants now.
4 of the studies in Heart Failure by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07656454Novo Nordisk A/SA Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy Participants | 2026-12-31 |
| NCT07218627Novo Nordisk A/SA Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure | 2027-01-15 |
| NCT06979375Novo Nordisk A/SA Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy | 2027-05-16 |
| NCT06979362Novo Nordisk A/SA Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy | 2027-11-16 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies in Heart Failure by Novo Nordisk A/S, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase I, randomized, double-blind, placebo-controlled study to assess safety, pharmacokinetics and pharmacodynamic parameters of CDR132L in patients with stable heart failure of ischemic origin (NYHA 1-3).
Objectives:
Primary
Secondary • To characterize the pharmacokinetic (PK) profile of CDR132L in patients with stable heart failure of ischemic origin.
Exploratory
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: CDR132L
Drug: CDR132L
i.v. administration
Incidence of treatment-emergent adverse events [safety and tolerability]
The incidence and severity of treatment-emergent adverse events (TEAEs)
Time frame: 4 months
Maximum plasma concentration (Cmax)
Pharmacokinetics parameter derived by non-compartmental methods to measure maximum observed plasma concentration (Cmax)
Time frame: 4 months
Time to reach maximum plasma concentration (Tmax)
Pharmacokinetics parameter derived by non-compartmental methods to measure time to maximum plasma concentration (Tmax)
Time frame: 4 months
Area under the curve (AUC0-t)
Pharmacokinetics parameter area under the plasma concentration-time curve from time zero to last detectable plasma concentration (AUC0-t)
Time frame: 4 months
Area under the curve (AUC0-inf)
Pharmacokinetics parameter area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-inf)
Time frame: 4 months
Blood clearance (CL)
Pharmacokinetics parameter to determin clearance considering terminal elimination rate
Time frame: 4 months
Half life (t1/2)
Pharmacokinetics parameter to determin half-life rate (t1/2)
Time frame: 4 months
Volume of distribution (Vdss)
Pharmacokinetics parameter
Time frame: 4 months
Plan to share: No
Ran from Jun 2019 to primary completion in Jan 2020, 7 months.
Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 7 months is close to that.
Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CDR132L
Cardior Pharmaceuticals GmbH →